Oncodesign announced today the strengthening of its Board of Directors with the appointment of Aline Aubertin as a new independent director. Her appointment was approved at the Combined General Meeting of June 24, 2021.
Servier and Oncodesign (ALONC – FR0011766229) (Paris:ALONC) have announced a strategic partnership for the research and development of potential drug candidates for Parkinson's disease.